NCT/Study#
NCT03215030 /
TAK-573-1501
A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma
DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
